Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

This study compares a combination of two drugs (oral azacitidine plus romidepsin) against the doctor's choice of standard treatment for people with peripheral T-cell lymphoma (PTCL) — a type of aggressive blood cancer — that has come back or stopped responding after prior therapy. **You may be eligible if...** - You have been diagnosed with relapsed or refractory peripheral T-cell lymphoma (confirmed by biopsy) - Your lymphoma has come back after at least one, but no more than three, prior treatment regimens - You are 18 or older with adequate organ function - You have at least one measurable tumor that can be tracked on imaging **You may NOT be eligible if...** - You have already had more than 3 prior lines of therapy - You have had a prior allogeneic (donor) stem cell transplant - You have significant heart problems (prolonged QT interval) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.